Opinion

Video

Which Symptoms are Most Burdensome to Patients With AD

Andrea Nguyen, PA, shares which symptoms are most burdensome to patients with AD.

This is a video synopsis/summary of a panel discussion involving Melodie Young, NP, and Andrea Nguyen, PA.

In this clinical discussion, the focus is on the signs and symptoms that prompt patients, or their family members, to seek dermatological care for atopic dermatitis (AD). The conversation addresses the diverse complaints associated with AD and emphasizes the burden of symptoms on patients' lives.

The experts highlight key features that may trigger considerations of AD, including an early age of onset, family history, and elevated IgE (allergen-specific immunoglobulin E) levels. Dryness of the skin and lichenification are also indicative factors. The hallmark and burdensome symptom of AD is pruritus, constituting a major diagnostic criterion. It is described as constant, chronic, and a source of significant distress for patients. The fear of flares, with periods of exacerbation, contributes to interrupted sleep and sleep deprivation, affecting both children and adults.

The experts underscore the impact of AD on patients' daily lives, with children experiencing difficulty concentrating in school due to itchiness. Sleep disturbance is a common issue for both patients and parents, influencing overall quality of life. The damaged skin barrier in AD patients increases the risk of skin infections, prompting visits to urgent care clinics and primary care providers. This discussion provides valuable insights into the symptomatic landscape of AD, shedding light on the challenges patients face and the multidisciplinary expertise required for effective management.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.